Undisclosed Neurodegeneration Program(s)
Alzheimer's Disease, Parkinson's Disease
PreclinicalActive
Key Facts
Indication
Alzheimer's Disease, Parkinson's Disease
Phase
Preclinical
Status
Active
Company
About Muna Therapeutics
Muna Therapeutics is a private, preclinical-stage biotech founded in 2020, targeting high-unmet-need neurodegenerative diseases with small molecule drugs. The company leverages a team with deep neurology drug discovery experience and is supported by world-class scientific founders and advisors. Its core mission is to develop disease-modifying therapies that alter the course of Alzheimer's and Parkinson's diseases, representing a significant market opportunity.
View full company profileTherapeutic Areas
Other Alzheimer's Disease, Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| DJ-1 / PARK7 Program | Cantabio Pharmaceuticals | Pre-clinical |
| Neurodegenerative Diseases Biomarker Services | The Siesta Group | Service Offering |
| Undisclosed Neurodegeneration Program | Sitala Bio | Pre-clinical |